Skip to main content

Table 3 Multivariable model of variables associated with discontinuation of endocrine therapy among women who were eligible for Oncotype Dx testing (N = 3949)

From: Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

  HR (95% CI) P
Tested    0.10
 Yes 0.93 (0.85–1.02)  
 No (ref)    
Year diagnosed    <0.001
 2006–2007 (ref)    
 2008–2009 1.62 (1.48–1.78)  
 2010 2.71 (2.37–3.11)  
Age at diagnosis, years    0.002
 24–39 (ref)    
 40–49 0.75 (0.65–0.88)  
 50–59 0.74 (0.63–0.88)  
 60–63 0.80 (0.66–0.97)  
Race-ethnicity    0.03
 NH white (ref)    
 NH black 1.32 (1.08–1.61)  
 Hispanic 1.09 (0.90–1.34)  
 Other 0.93 (0.80–1.08)  
Marital status    0.01
 Married (ref)    
 Not married 1.11 (1.02–1.21)  
Prior cancer    0.87
 No (ref)    
 Yes 1.02 (0.85–1.22)  
State    <0.001
 CA (ref)    
 GA 1.01 (0.87–1.17)  
 KY 0.81 (0.68–0.95)  
 NY 0.77 (0.66–0.90)  
 OH 0.86 (0.73–1.00)  
Area    0.36
 Rural (ref)    
 Urban 0.92 (0.77–1.10)  
Median household income   <0.001
 1 (lowest (ref))    
 2 0.99 (0.87–1.13)  
 3 0.99 (0.87–1.12)  
 4 0.93 (0.82–1.06)  
 5 (highest) 0.76 (0.66–0.88)  
Stage    0.43
 I (ref)    
 II 1.05 (0.93–1.18)  
Nodal involvement    0.36
 N0 1.09 (0.95–1.25)  
 N1mic 0.97 (0.82–1.15)  
 N1 (ref)    
HER2 status    0.61
 Negative 0.95 (0.84–1.08)  
 Borderline 1.08 (0.76–1.55)  
 Unknown (ref)    
Hormone receptor status    0.69
 ER and PR both positive (ref)    
 Only ER or PR positive 1.02 (0.91–1.15)  
Histological grade    0.17
 1–2 (well/moderately differentiated) (ref)    
 3 (poorly or not differentiated) 1.07 (0.97–1.18)  
One year comorbidities    0.01
 0 (ref)    
 1 or more 1.17 (1.03–1.32)  
Surgery type    0.79
 Breast-conserving surgery (ref)    
 Mastectomy 1.01 (0.93–1.10)  
Endocrine therapy    <0.001
 Tamoxifen only (ref)    
 AIs only 0.77 (0.70–0.87)  
 Tamoxifen and AIs 0.76 (0.68–0.85)  
Chemotherapy    0.82
 Yes 1.01 (0.92–1.11)  
 No (ref)    
  1. Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node cancer that can only be seen under a microscope (<2 mm in size); N1 cancer at least 2 mm in size in at least one of three axillary lymph nodes. ref reference, NH non-Hispanic, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor, AI aromatase inhibitor